Jefferies is initiating coverage of Veradermics with a 'buy' rating, betting that a smarter formulation of an old drug could unlock a $2 billion market
Minoxidil has been around for decades. Millions of people rub it into their scalps every day, and a growing number take low-dose oral versions off-label. Yet no pharmaceutical company has ever secured Food & Drug Administration approval for a hair loss pill in either men or women. Veradermics wants to change that.
The company's lead asset, VDPHL01, is an extended-release formulation of minoxidil designed to solve a problem that has long limited the drug's appeal: it works, but the pharmacokinetics are messy.
Standard immediate-release minoxidil surges through the bloodstream quickly, hitting peaks that have been linked to cardiac activity in early studies, and then drops below effective concentrations within hours.
VDPHL01's extended-release design aims to keep plasma levels above the roughly 1-2 ng/mL threshold associated with hair growth for up to 15-24 hours, while staying below the approximately 20 ng/mL level flagged as a cardiac concern. Jefferies argues that no patients in Phase 1 and 2 trials exceeded that threshold, a claim that cannot be made for the immediate-release version.
What the data need to show
First pivotal trial results for men are expected in the first half of 2026. Jefferies is expects to see statistically significant hair count gains alongside meaningful patient-reported improvements. A second male trial and a female trial are expected to read out through 2026 and 2027.
The female indication is where analysts see the most upside. There is no approved oral option for women with pattern hair loss, a population that has been largely overlooked.
The commercial case
Jefferies sets a 12-month price target of $75, roughly 75% above current levels, with a bull case reaching $111. The drug would be cash-pay only, sold direct to consumers rather than through insurance. For a company that counts Eli Lilly as an anchor IPO investor, the commercial infrastructure is at least partially validated before a single prescription is written.